Advertisement

CD95 pp 1-10 | Cite as

Production of the Non-apoptotic Metalloprotease-Cleaved CD95L and Its Cytotoxic Recombinant Counterpart Designed Ig-CD95L

  • Eléonore Lepvrier
  • Sophie Martin
  • Brigitte Collet
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1557)

Abstract

The ligand of CD95, CD95L (also known as FasL or CD178), is a type II transmembrane protein that belongs to the Tumor Necrosis factor (TNF) family (Fig. 1a). This membrane-bound cytokine is mainly expressed at the surface of activated T lymphocytes and natural killer cells, where it is used as an apoptotic factor to eliminate infected and transformed cells (Strasser et al., Immunity 30:180–192, 2009).

Key words

FasL CD95 CD95L Tumor Necrosis factor 

References

  1. 1.
    Strasser A, Jost PJ, Nagata S (2009) The many roles of FAS receptor signaling in the immune system. Immunity 30(2):180–192CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Tanaka M, Suda T, Takahashi T, Nagata S (1995) Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J 14(6):1129–1135PubMedPubMedCentralGoogle Scholar
  3. 3.
    Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O, Thiemann M, Mueller W, Sykora J, Kuhn A, Schreglmann N, Letellier E, Zuliani C, Klussmann S, Teodorczyk M, Grone HJ, Ganten TM, Sultmann H, Tuttenberg J, von Deimling A, Regnier-Vigouroux A, Herold-Mende C, Martin-Villalba A (2008) Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 13(3):235–248CrossRefPubMedGoogle Scholar
  4. 4.
    Malleter M, Tauzin S, Bessede A, Castellano R, Goubard A, Godey F, Leveque J, Jezequel P, Campion L, Campone M, Ducret T, Macgrogan G, Debure L, Collette Y, Vacher P, Legembre P (2013) CD95L cell surface cleavage triggers a prometastatic signaling pathway in triple-negative breast cancer. Cancer Res 73(22):6711–6721CrossRefPubMedGoogle Scholar
  5. 5.
    Tauzin S, Chaigne-Delalande B, Selva E, Khadra N, Daburon S, Contin-Bordes C, Blanco P, Le Seyec J, Ducret T, Counillon L, Moreau JF, Hofman P, Vacher P, Legembre P (2011) The naturally processed CD95L elicits a c-yes/calcium/PI3K-driven cell migration pathway. PLoS Biol 9(6):e1001090CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Legembre P, Beneteau M, Daburon S, Moreau JF, Taupin JL (2003) Cutting edge: SDS-stable Fas microaggregates: an early event of Fas activation occurring with agonistic anti-Fas antibody but not with Fas ligand. J Immunol 171(11):5659–5662CrossRefPubMedGoogle Scholar
  7. 7.
    Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S, Gaide O, Martinon F, Tinel A, Deperthes D, Calderara S, Schulthess T, Engel J, Schneider P, Tschopp J (2003) Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol 23(4):1428–1440CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Chaigne-Delalande B, Mahfouf W, Daburon S, Moreau JF, Legembre P (2009) CD95 engagement mediates actin-independent and -dependent apoptotic signals. Cell Death Differ 16(12):1654–1664CrossRefPubMedGoogle Scholar
  9. 9.
    Daburon S, Devaud C, Costet P, Morello A, Garrigue-Antar L, Maillasson M, Hargous N, Lapaillerie D, Bonneu M, Dechanet-Merville J, Legembre P, Capone M, Moreau JF, Taupin JL (2013) Functional characterization of a chimeric soluble Fas ligand polymer with in vivo anti-tumor activity. PLoS One 8(1):e54000CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2017

Authors and Affiliations

  1. 1.Centre Eugène MarquisRennesFrance
  2. 2.INSERM ERL440-OSSEquipe Labellisée Ligue Contre Le CancerRennesFrance
  3. 3.Université de Rennes-1RennesFrance

Personalised recommendations